Early treatment of highly active multiple sclerosis improves outcomes, according to research sponsored by Biogen.

Researchers compared 233 patients who began natalizumab within a year of the onset of MS symptoms with 179 and 144 patients who started it one to five years and more than five years after symptoms emerged. Over three years, the likelihood of worsening on the expanded disability status scale (EDSS), which assesses MS severity, did not differ significantly between the groups.

However, the likelihood of confirmed 24-week improvement in EDSS was significantly greater for those patients who received natalizumab within a year of MS symptoms emerging (49.3 per cent) than for those treated between one to five years (38.1 per cent) or more than five years (26.3 per cent) following symptom onset.

Natalizumab reduced the annualised relapse rate by about 93 per cent in all three groups.

The authors suggest that, “disability early in the course of MS may reflect inflammation that can be mitigated by timely treatment with natalizumab, whereas later disability may be more resistant to recovery”.

Originally Published by Pharmacy Magazine

Recommended

Treating tobacco dependance

This CPD module provides an overview of helping patients deal with tobacco dependance

Patient safety part two

This is the second CPPE module in our series on patient safety.

Popular

NHS moves to tackle medication errors

To help the NHS monitor medication errors, a series of indicators are being introduced to show whether a prescription ma...

Measles warning

The increase in measles circulation is mainly associated with travel to and from Europe where there are large ongoing me...

NHS well placed to integrate care

The NHS probably has a better chance to truly integrate care than almost any other health care system in the world, a fo...